Trial Profile
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs ATL 101 Telix Pharmaceuticals (Primary) ; Hydrocortisone; J 591-radiolabelled; Ketoconazole
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 18 Feb 2023 Results assessing that 177Lu prolongs 18-month (mo) met-free survival (MFS) more than 111In in patients with high-risk non-metastatic castration-resistant prostate cancer, presented at the 2023 Genitourinary Cancers Symposium
- 18 Feb 2023 Results assessing 177Lu prolongs 18-month (mo) met-free survival (MFS) more than 111In in pts with high risk, M0 CRPC when targeting PSMA via J591 in combo with keto and HC presented at the 2023 Genitourinary Cancers Symposium
- 25 Mar 2022 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.